BACKGROUND: In @entity1577 ( @entity1577 ) @entity1224 and recurrent @entity1729 lead to @entity32 , long-term lung damage, @entity1576 and @entity204 . Anti-inflammatory agents, e.g. oral @entity288 are used since @entity32 occurs early in disease. This is an update of a previously published review. OBJECTIVES: To assess the effectiveness of oral @entity288 in @entity1576 in @entity1577 , particularly lung function and adverse events. We examined long-term use (over 30 days) only. SEARCH METHODS: We searched the Cochrane @entity1577 and @entity74 Group Trials Register comprising references identified from comprehensive electronic database searches and handsearches of relevant journals and abstract books of conference proceedings.Most recent search: 28 August 2015. SELECTION CRITERIA: Randomised trials comparing oral @entity288 given for more than 30 days with placebo or no additional therapy in @entity1 with @entity1577 . DATA COLLECTION AND ANALYSIS: Two authors independently assessed study eligibility and quality. MAIN RESULTS: Of eleven studies identified, three (354 @entity1 ) were included: two with four-year follow up and one with 12-weeks follow up. Data were lacking on predefined outcomes; common outcomes were examined at different time-points and presented differently. Meta-analyses were not possible.In one study, oral @entity288 at @entity617 -equivalent dose of 1 mg/kg alternate days slowed @entity358 ; at two and four years, % predicted FEV1 in the 1 mg/kg group changed significantly more than in the placebo group (P < 0.02). During the first two years, the 2 mg/kg group was not significantly different from the placebo group. @entity851 was observed from six months in the 2 mg/kg alternate days @entity617 group and from 24 months in the 1 mg/kg alternate days @entity617 group.Adverse events terminated one four-year study early. Year 10 follow up showed catch-up growth started two years after treatment ceased. Alternate-day treatment with oral @entity288 may have impaired growth until adulthood in @entity1 . AUTHORS' CONCLUSIONS: Oral @entity288 at @entity617 -equivalent dose of 1 to 2 mg/kg alternate days appear to slow @entity358 in @entity1577 ; benefit should be weighed against occurrence of adverse events. Risk-benefit analysis of low-dose alternate days @entity288 is important. No further trials of this intervention are anticipated, and hence the review will no longer be regularly updated. However, if any new data are published, these will be incorporate when available.

Oral steroids for long-term use in XXXX .

@entity1 :: ('9606', 'Species') :: ['participants', 'boys', 'people'] @entity32 :: ('MESH:D007249', 'Disease') :: ['inflammation'] @entity851 :: ('MESH:D006130', 'Disease') :: ['Linear growth retardation'] @entity358 :: ('MESH:D008171', 'Disease') :: ['progression of lung disease'] @entity1576 :: ('MESH:D012131', 'Disease') :: ['respiratory failure', 'respiratory complications'] @entity1729 :: ('MESH:D012141', 'Disease') :: ['respiratory infection'] @entity74 :: ('MESH:D030342', 'Disease') :: ['Genetic Disorders'] @entity617 :: ('MESH:D011239', 'Chemical') :: ['prednisolone'] @entity204 :: ('MESH:D003643', 'Disease') :: ['death'] @entity1577 :: ('MESH:D003550', 'Disease') :: ['CF', 'cystic fibrosis'] @entity1224 :: ('MESH:D000402', 'Disease') :: ['airway obstruction'] @entity288 :: ('MESH:D000305', 'Chemical') :: ['corticosteroids']
@entity1577 :: (MESH:D003550,Disease) :: ['cystic fibrosis']
